Trial Profile
Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 22 Mar 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results of an interim analysis (data cut off 25 April 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology